• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Regenxbio Inc (NQ: RGNX )

    11.56 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 11, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 266
    Open 11.56
    Bid (Size) 8.420 (4)
    Ask (Size) 12.33 (1)
    Prev. Close 11.56
    Today's Range 11.56 - 11.56
    52wk Range 8.535 - 28.80
    Shares Outstanding 43,466,186
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    What 4 Analyst Ratings Have To Say About Regenxbio
    Via Benzinga

    Performance

    YTD
    -36.97%
    -36.97%
    1 Month
    +13.33%
    +13.33%
    3 Month
    -3.26%
    -3.26%
    6 Month
    -26.56%
    -26.56%
    1 Year
    -34.84%
    -34.84%

    More News

    Read More
    Assessing Regenxbio: Insights From 5 Financial Analysts
    Via Benzinga
    New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
    Via FinancialNewsMedia
    Exposures COVID-19
    Where Regenxbio Stands With Analysts
    Via Benzinga
    Assessing Regenxbio: Insights From 4 Financial Analysts
    Via Benzinga
    Evaluating Regenxbio: Insights From 9 Financial Analysts
    Via Benzinga
    New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
    From FN Media Group LLC
    Via GlobeNewswire
    7 Biotech Stocks to Buy for Their Game-Changing Potential
    Via InvestorPlace
    Why Is Clearside Biomedical Stock Gaining Today?
    Via Benzinga
    Where Regenxbio Stands With Analysts
    Via Benzinga
    Beyond The Numbers: 4 Analysts Discuss Regenxbio Stock
    Via Benzinga
    7 Biotech Stocks to Buy on the Dip: June 2024
    Via InvestorPlace
    FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy
    Via Benzinga
    Exposures Product Safety
    Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy
    Via Investor's Business Daily
    Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
    Via Investor's Business Daily
    Exposures Product Safety
    Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
    Via Benzinga
    RGNX Stock Earnings: Regenxbio Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
    Via The Motley Fool
    This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO
    Via Benzinga
    REGENXBIO's Muscle Wasting Disorder Drug Shows Strength, Improved Motor Function, Stock Soars
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.